A recent study has found that sevelamer (Renagel®) is having a positive, long-term clinical and economic effect when used on hemodialysis patients.
This study, undertaken by the Caro Research Institute in Concord, Mass., and published in Value in Health, examined the long-term consequences associated with one year of sevelamer use.
According to Krista Huybrechts, who led the study, "the safety and efficacy of sevelamer and its ability to attenuate the progression of calcification have been well-documented in a seminal clinical study, but the study was not designed to assess the longer-term implications."
Huybrechts' team developed a simulation model based on the best available evidence to date, and estimated that in the long term, patients on sevelamer have a 12 percent lower cardiovascular risk than those on calcium binders.The cost savings accrued due to avoiding cardiovascular events largely offset the higher drug price, leading to a very favorable cost-effectiveness ratio of about $2,200 of increased cost per life year gained.
The results of this study now allow health-policy makers and payers to understand the value of sevelamer in the long-term.
Nearly 500,000 Americans suffer from Stage V chronic kidney disease, and have a 10 to 20 times higher risk of cardiovascular mortality than the general population.